gdc
Colorectal Cancer

Drugs for Colorectal Cancer

Here are the financial support services available to patients receiving treatment for Colorectal Cancer.

Avastin (bevacizumab)

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used as a first-line or second-line treatment for patients with metastatic colorectal cancer, together with IV chemotherapy. Avastin is also used as a second-line treatment, in combination with other types of chemotherapy, in patients with metastatic colorectal cancer whose disease progressed with a first-line Avastin-containing regimen.

Genentech provides 2 financial assistance programs for patients who are using Avastin:

Genentech BioOncology Co-pay Card

With this program, patients with private insurance pay a $25 copay, and up to $25,000 is paid by the program annually; there are no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $100,000. Avastin is also provided free of charge for patients whose household income is less than $150,000 if their out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).

Camptosar (irinotecan hydrochloride injection)

Drug company: Pfizer
844-989-7284

Camptosar is a topoisomerase inhibitor used as a first-line therapy, in combination with a chemotherapy regimen, for patients with metastatic carcinoma of the colon or the rectum (colorectal cancer). Camptosar is also used for patients with metastatic carcinoma of the colon or rectum whose disease has returned or progressed after chemotherapy.

Pfizer provides 1 financial assistance program for patients using Camptosar:

Pfizer Patient Assistance Program

Patients who are prescribed a Pfizer specialty medicine, such as Camptosar, and meet certain income limits but have no drug perscription coverage or insufficient coverage to pay for Camptosar, can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.

Cyramza (ramucirumab)

Drug company: Eli Lilly
866-472-8663

Cyramza is a human VEGF receptor 2 antagonist used in combination with chemotherapy for patients with metastatic colorectal cancer that progressed during or after therapy with Avastin, Eloxatin, and a fluoropyrimidine.

Lilly PatientOne provides 2 financial assistance programs for patients using Cyramza:

Lilly PatientOne Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose of Cyramza.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and a household income up to 500% or less of the federal poverty level, this program provides Cyramza at no cost.

Eloxatin (oxaliplatin)

Drug company: Sanofi
888-847-4877

Eloxatin is a platinum-based drug used in combination with IV chemotherapy as an adjuvant treatment for patients with stage III colon cancer who have undergone complete resection (surgical removal) of the primary tumor, or as treatment for advanced colorectal cancer.

(Sanofi does not provide a specific financial assistance program for Eloxatin.)

Erbitux (cetuximab)

Drug company: Eli Lilly
866-472-8663

Erbitux is an EGFR antagonist used for the treatment of patients with KRAS wild-type, EGFR-expressing, metastatic colorectal cancer in combination with a chemotherapy regimen for first-line treatment, in combination with Camptosar for patients who cannot use Camptosar-based chemotherapy, or as a single drug for patients who have not benefited from Eloxatin- and Camptosar-based chemotherapy, or who cannot use Camptosar.

Lilly PatientOne provides 2 financial assistance programs for patients using Erbitux:

Lilly PatientOne Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose of Erbitux.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and a household income up to 500% or less of the federal poverty level, this program provides Erbitux at no cost.

Fusilev (levoleucovorin)

Drug company: Spectrum
888-537-8277

Fusilev is a folate analog used in combination with chemotherapy (5-fluorouracil) for palliative treatment of patients with advanced metastatic colorectal cancer.

Spectrum Therapy Access Resources provides 2 financial assistance programs for patients using Fusilev:

STAR Patient Assistance Program

This patient assistance program provides Fusilev free of charge to patients who meet the income, insurance, and citizenship or residency eligibility criteria.

STAR Co-pay Assistance

STAR provides financial assistance to privately insured patients who apply for assistance and receive approval before receiving outpatient therapy.

Lonsurf (trifluridine and tipiracil) Tablets

Drug company: Taiho
844-824-4648

Lonsurf is a nucleoside metabolic inhibitor and thymidine phosphorylase inhibitor used for patients with metastatic colorectal cancer who have previously received chemotherapy, an anti-VEGF biological therapy, and if their cancer is KRAS wild-type, an anti-EGFR therapy.

Taiho Oncology Patient Support provides 2 financial assistance programs for patients using Lonsurf:

Taiho Oncology Patient Support Co-pay Card

Patients with private insurance may be eligible to receive a copay card to help them to pay $30 out-of-pocket expenses for a treatment cycle of Lonsurf.

Taiho Oncology Patient Support Program

This program may provide Lonsurf free of charge for patients who have no insurance or insufficient prescription coverage and insufficient financial resources.

Opdivo (nivolumab)

Drug company: Bristol-Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer that has progressed after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan regimen.

Bristol-Myers Squibb (BMS) Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductibles, copay, or coinsurance costs for eligible patients with private insurance who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol-Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Opdivo, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $35,640 for an individual or $48,060 for a family of 2.

Stivarga (regorafenib) Tablets

Drug company: Bayer
866-639-2827

Stivarga is a kinase inhibitor used for patients with metastatic colorectal cancer who have previously received either chemotherapy, an anti-VEGF therapy, or if their cancer is RAS wild-type (no RAS mutation), an anti-EGFR therapy.

Bayer provides 2 financial assistance programs for patients using Stivarga:

Stivarga $0 Co-pay Program

Through this program, patients with private insurance will have a $0 copay for Stivarga, up to $25,000 per patient annually.

REACH Patient Assistance Program

Uninsured or underinsured patients who are prescribed Stivarga should contact the Resources for Expert Assistance and Care Helpline (REACH) services counselor to possibly qualify for free medication.

Vectibix (panitumumab)

Drug company: Amgen
888-427-7478

Vectibix is an EGFR antagonist used for patients with KRAS wild-type metastatic colorectal cancer as first-line treatment in combination with a chemotherapy regimen, or alone when their disease progresses after treatment with a chemotherapy regimen.

Amgen provides 2 financial assistance programs for patients using Vectibix:

Vectibix First Step Program

For patients with private insurance whose insurance covers Vectibix, this program ensures a copay of $0 for the first dose and $25 for each dose thereafter, with a maximum benefit of $10,000 per patient, annually.

Amgen Safety Net Foundation

Patients with limited or no drug coverage and patients with Medicare Part D who satisfy the income eligibility requirements can receive Vectibix for free through this nonprofit program from Amgen.

Xeloda (capecitabine) Tablets

Drug company: Genentech
866-422-2377

Xeloda is a nucleoside metabolic inhibitor with antineoplastic activity used as adjuvant treatment for patients with Dukes’ C colon cancer, and as a first-line therapy alone for patients with metastatic colorectal cancer when treatment with fluoropyrimidine therapy alone is preferred.

(Genentech does not provide a specific financial support program for Xeloda.)

Zaltrap (ziv-aflibercept)

Drug company: Sanofi
888-847-4877

Zaltrap, in combination with a chemotherapy regimen, is used for patients with metastatic colorectal cancer that is resistant to or has progressed after an Eloxatin-containing regimen.

The Sanofi Patient Connection provides 1 financial assistance program for patients using Zaltrap:

Sanofi Patient Connection

Patients who are uninsured or whose insurance does not cover Zaltrap can apply for financial assistance through this program. Eligible patients must have an annual household income of no more than 500% of the current poverty level. Patients with Medicare Part D can apply if they are not eligible for low income subsidy and have out-of-pocket drug costs that equal 5% or more of their annual income.

Table. Drugs Prescribed for Colorectal Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Avastin (bevacizumab)
  • Drug company
  • Genentech
  • Indication
  • First-line or second-line therapy for metastatic colorectal cancer, in combination with IV-based chemotherapy

    Second-line treatment, in combination with a chemotherapy regimen, for metastatic colorectal cancer that progressed with first-line Avastin-containing regimen
  • Patient support services
  • Genentech BioOncology Co-pay Card
    855-692-6729

    Genentech Access to Care Foundation
    866-422-2377

    Drug name (generic name)
  • Camptosar (irinotecan hydrochloride injection)
  • Drug company
  • Pfizer
  • Indication
  • First-line therapy for metastatic carcinoma of the colon or rectum, in combination with 5-fluorouracil and leucovorin

    Second-line therapy for metastatic carcinoma of the colon or rectum, after chemotherapy
  • Patient support services
  • Pfizer Patient Assistance Program
    844-989-7284


    Drug name (generic name)
  • Eloxatin (oxaliplatin)
  • Drug company
  • Sanofi
  • Indication
  • Adjuvant treatment of stage III colon cancer after surgical removal of the tumor, in combination with chemotherapy

    Advanced colorectal cancer, in combination with chemotherapy
  • Patient support services
  • (No specific program)
    888-847-4877

    Drug name (generic name)
  • Erbitux (cetuximab)
  • Drug company
  • Eli Lilly
  • Indication
  • First-line treatment for metastatic colorectal cancer, in combination with chemotherapy

    Metastatic colorectal cancer, in combination with Camptosar

    Metastatic colorectal cancer, after chemotherapy or if unable to use Camptosar
  • Patient support services
  • Lilly PatientOne Co-pay Program
    866-472-8663

    Lilly Cares Foundation Patient Assistance Program
    800-545-6962

    Drug name (generic name)
  • Fusilev (levoleucovorin)
  • Drug company
  • Spectrum
  • Indication
  • Palliative treatment for advanced metastatic colorectal cancer, in combination with chemotherapy
  • Patient support services
  • STAR Patient Assistance Program
    888-537-8277

    STAR Co-pay Assistance
    888-537-8277




    Drug name (generic name)
  • Vectibix (panitumumab)
  • Drug company
  • Amgen
  • Indication
  • First-line therapy of metastatic colorectal cancer, in combination with chemotherapy

    Metastatic colorectal cancer, after chemotherapy
  • Patient support services
  • Vectibix First Step Program
    888-657-8371

    Amgen Safety Net Foundation
    888-762-6436

    Drug name (generic name)
  • Xeloda (capecitabine) Tablets
  • Drug company
  • Genentech
  • Indication
  • Adjuvant therapy for colon cancer, specifically Dukes’ C colon cancer

    First-line therapy for metastatic colorectal cancer
  • Patient support services
  • (No specific program)
    866-422-2377

    Drug name (generic name)
  • Zaltrap (ziv-aflibercept)
  • Drug company
  • Sanofi
  • Indication
  • Metastatic colorectal cancer, after chemotherapy
  • Patient support services
  • Sanofi Patient Connection
    888-847-4877

Last modified: April 16, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country